Today

Agents

Chat

Arena

Discover

More

App

AbbVie Announces European Commission Approval Of RINVOQ (Upadacitinib) - ABBV News | Rallies

AbbVie Announces European Commission Approval Of RINVOQ (Upadacitinib)

ABBV•2026-09-22

European Commission approves RINVOQ for pediatric arthritis

Sept. 22 (Reuters) - AbbVie Inc. ABBV.N:

AbbVie announces European Commission approval of RINVOQ® (upadacitinib) for the treatment of children with active polyarticular juvenile idiopathic arthritis
AbbVie - RINVOQ approved in the EU for pJIA in patients aged two years and older

Source text: ID:nPn4Vqq9sa

Further company coverage: ABBV.N

Related News

Gold muted as higher-for-longer rate outlook weighs

GLD•2026-09-22

FactSet <FDS.N>: Jefferies Raises Target Price to $285 From $253

FDS•2026-09-22

Nasdaq trade halt continues <MAGH.O> reason not available at 03:58 AM

2026-09-22

Kinder Morgan, Inc. <KMI.N>: RBC Raises Target Price to $36 From $35

KMI•2026-09-22

Europe before the bell: futures steady after Nasdaq's 3% jump

QQQ•2026-09-22